1. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy
- Author
-
Carlo Giaquinto, Giovanni Gabutti, Vincenzo Baldo, Marco Villa, Lara Tramontan, Nadia Raccanello, Francesca Russo, Chiara Poma, Antonio Scamarcia, Luigi Cantarutti, Rebecca Lundin, Emilia Perinetti, Xavier Cornen, Stéphane Thomas, Céline Ballandras, Audrey Souverain, and Susanne Hartwig
- Subjects
Varicella ,Vaccine ,Effectiveness ,Impact ,ProQuad ,Italy ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Monovalent varicella vaccines have been available in the Veneto Region of Italy since 2004. In 2006, a single vaccine dose was added to the immunisation calendar for children aged 14 months. ProQuad®, a quadrivalent measles-mumps-rubella-varicella vaccine, was introduced in May 2007 and used, among other varicella vaccines, until October 2008. This study aimed to evaluate the effectiveness of a single dose of ProQuad, and the population impact of a vaccination program (VP) against varicella of any severity in children who received a first dose of ProQuad at 14 months of age in the Veneto Region, Methods All children born in 2006/2007, i.e., eligible for varicella vaccination after ProQuad was introduced, were retrospectively followed through individual-level data linkage between the Pedianet database (varicella cases) and the Regional Immunization Database (vaccination status). The direct effectiveness of ProQuad was estimated as the incidence rate of varicella in ProQuad-vaccinated children aged
- Published
- 2018
- Full Text
- View/download PDF